Sun Pharma Q2 Consolidated Net Income Falls to 19.89 Billion Rupees Despite 11.8% Sales Growth

Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) reported lower consolidated net earnings for the second quarter on Friday, with net income falling to 19.885 billion Indian rupees from 31.180 billion rupees a year ago. Earnings per share were 8.3 rupees versus 13.0 rupees in the prior-year period. Consolidated adjusted profit rose 1.4% to 31.620 billion rupees. Sales climbed 11.8% to 161.000 billion rupees, and total income rose to 167.160 billion rupees from 149.482 billion rupees. EBITDA grew 4.8% to 47.439 billion rupees, though the EBITDA margin narrowed to 29.3% from 31.3%. Gross margin improved to 80.8% from 79.3%. On a standalone basis, quarterly profit was 8.713 billion rupees, or 3.6 rupees per share, up from 5.642 billion rupees, or 2.4 rupees per share. Sun Pharma closed Friday's regular trading on the NSE at 1,777.70 rupees, up 0.95%.